Total
0
Shares
Nyrada (ASX:NYR) - CEO, James Bonnar - The Market Herald
CEO, James Bonnar
Source: Finance News Network
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Nyrada’s (NYR) new lead drug candidate has advanced to efficacy studies with the Walter Reed Army Institute of Research (WRAIR)
  • The company says its new drug, NYR-BI01, is more potent than its predecessor
  • The new candidate displayed high potency in a biological assay and impressive characteristics during a pharamacokinetic study, indicating that the drug can be well-tolerated
  • Nyrada is down 3.17 per cent, trading at 30.5 cents at 1:00 pm AEST

Nyrada’s (NYR) new lead drug candidate has advanced to efficacy studies with the Walter Reed Army Institute of Research (WRAIR).

The company says its new drug, NYR-BI01, is more potent than its predecessor, NYX-1010.

Nyrada says the new candidate showed high potency in a biological assay and impressive characteristics during a pharamacokinetic study, intended to determine the level at which it penetrates the brain.

In the study, the treatment was administered to uninjured animals via continuous intravenous infusion at two doses for 72 hours, assessing blood concentrations and brain penetration — a duration that aligns with the therapeutic window for preventing secondary brain injury in patients.

The company says no adverse effects were observed in the animals at either dose level, and no significant changes were observed in markers of liver and kidney function or body weight, indicating that the drug is well-tolerated even at the higher dose. 

“Crossing the blood-brain-barrier at above therapeutic levels with a newly improved and highly potent drug candidate means our drug can reach the area of the brain damaged by traumatic brain injury,” said Nyrada CEO James Bonnar.

“This focus on optimising our drug in preclinical studies enables us to take the best candidate into our studies with WRAIR and eventually into human clinical trials, giving us the best chance of success in Phase I.”

Nyrada is down 3.17 per cent, trading at 30.5 cents at 1:00 pm AEST.

NYR by the numbers
More From The Market Herald
Rhythm Biosciences (ASX:RHY) brings ColoSTAT trial to Queensland

" Proteomics International Laboratories (ASX:PIQ) to collaborate for world’s first endometriosis test

Proteomics International Laboratories (PIQ) has penned a research agreement to develop a non-invasive test for endometriosis.
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating - The Market Herald

" ResApp Health (ASX:RAP) secures two deals to integrate its diagnostic test

ResApp Health (RAP) has secured two new agreements for its smartphone-based acute respiratory diagnostic test.
Paradigm Biopharmaceuticals (ASX:PAR) - Chairman & CEO, Paul Rennie - The Market Herald

" FDA requests further clarification from Paradigm Biopharmaceuticals (ASX:PAR)

The US Food and Drug Administration has requested further clarification from Paradigm Biopharmaceuticals (PAR) for its Investigational New Drug (IND) application.
Patrys (ASX:PAB) - CEO and Managing Director, Dr James Campbell - The Market Herald

" Patrys’ (ASX:PAB) clinical trials pushed back

Patrys’ (PAB) planned PAT-DX1 clinical trial will be postponed for up to six months due to global manufacturing and supply chain delays.